[go: up one dir, main page]

DK1658858T4 - Anvendelse af botulinumtoksin til behandling af rekalcitrant tømningsdysfunktion - Google Patents

Anvendelse af botulinumtoksin til behandling af rekalcitrant tømningsdysfunktion

Info

Publication number
DK1658858T4
DK1658858T4 DK05024445.8T DK05024445T DK1658858T4 DK 1658858 T4 DK1658858 T4 DK 1658858T4 DK 05024445 T DK05024445 T DK 05024445T DK 1658858 T4 DK1658858 T4 DK 1658858T4
Authority
DK
Denmark
Prior art keywords
botulinum toxin
recalcitrant
treatment
dysfunction
emptying
Prior art date
Application number
DK05024445.8T
Other languages
English (en)
Other versions
DK1658858T3 (da
Inventor
Richard A Schmidt
Original Assignee
Univ Colorado
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21978526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1658858(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Colorado filed Critical Univ Colorado
Application granted granted Critical
Publication of DK1658858T3 publication Critical patent/DK1658858T3/da
Publication of DK1658858T4 publication Critical patent/DK1658858T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK05024445.8T 1997-07-15 1998-07-15 Anvendelse af botulinumtoksin til behandling af rekalcitrant tømningsdysfunktion DK1658858T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5258097P 1997-07-15 1997-07-15
EP98933345A EP1011695B2 (en) 1997-07-15 1998-07-15 Use of neurotoxin therapy for treatment of prostate disorders

Publications (2)

Publication Number Publication Date
DK1658858T3 DK1658858T3 (da) 2010-04-06
DK1658858T4 true DK1658858T4 (da) 2014-04-07

Family

ID=21978526

Family Applications (6)

Application Number Title Priority Date Filing Date
DK04026167.9T DK1502601T4 (da) 1997-07-15 1998-07-15 Anvendelse af neurotoksin-terapi til behandling af urinretention
DK04019371.6T DK1475099T4 (da) 1997-07-15 1998-07-15 Anvendelse af botulinum-toksin til behandling af urininkontinens
DK08154321.7T DK1949909T3 (da) 1997-07-15 1998-07-15 Anvendelse af botulinum-toksinterapi til behandling af dysfunktion af urge-typen
DK09175439.0T DK2145629T3 (da) 1997-07-15 1998-07-15 Anvendelse af neurotoksinterapi til behandling af urologiske og relaterede sygdomme
DK05024445.8T DK1658858T4 (da) 1997-07-15 1998-07-15 Anvendelse af botulinumtoksin til behandling af rekalcitrant tømningsdysfunktion
DK98933345.5T DK1011695T4 (da) 1997-07-15 1998-07-15 Anvendelse af neurotoksinterapi til behandling af prostata-lidelser

Family Applications Before (4)

Application Number Title Priority Date Filing Date
DK04026167.9T DK1502601T4 (da) 1997-07-15 1998-07-15 Anvendelse af neurotoksin-terapi til behandling af urinretention
DK04019371.6T DK1475099T4 (da) 1997-07-15 1998-07-15 Anvendelse af botulinum-toksin til behandling af urininkontinens
DK08154321.7T DK1949909T3 (da) 1997-07-15 1998-07-15 Anvendelse af botulinum-toksinterapi til behandling af dysfunktion af urge-typen
DK09175439.0T DK2145629T3 (da) 1997-07-15 1998-07-15 Anvendelse af neurotoksinterapi til behandling af urologiske og relaterede sygdomme

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK98933345.5T DK1011695T4 (da) 1997-07-15 1998-07-15 Anvendelse af neurotoksinterapi til behandling af prostata-lidelser

Country Status (16)

Country Link
US (5) US6365164B1 (da)
EP (8) EP1949909B1 (da)
JP (9) JP3692033B2 (da)
KR (1) KR100544060B1 (da)
CN (5) CN1480212B (da)
AT (5) ATE552006T1 (da)
AU (2) AU743085B2 (da)
CA (5) CA2521392A1 (da)
CY (3) CY1105816T1 (da)
DE (4) DE69833942T3 (da)
DK (6) DK1502601T4 (da)
ES (6) ES2256945T5 (da)
HK (4) HK1080377A1 (da)
LU (2) LU92055I2 (da)
PT (5) PT2145629E (da)
WO (1) WO1999003483A1 (da)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1480212B (zh) * 1997-07-15 2013-12-04 科罗拉多大学董事会 神经毒素疗法在泌尿系及相关疾病治疗中的应用
US9066943B2 (en) 1997-07-15 2015-06-30 The Regents Of The University Of Colorado Use of botulinum toxin therapy for treatment of urological neurological conditions
US7470431B2 (en) 1997-07-15 2008-12-30 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer
US7449192B2 (en) 1997-07-15 2008-11-11 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction
US7455845B2 (en) * 1997-07-15 2008-11-25 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure
US6450509B2 (en) * 1999-04-01 2002-09-17 Heeling Sports Limited Heeling apparatus and method
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US7838008B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US7838007B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
US6358513B1 (en) 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6773711B2 (en) 2000-02-15 2004-08-10 Allergan, Inc. Botulinum toxin therapy for Hashimoto's thyroiditis
US6524580B1 (en) 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6821520B2 (en) 2000-02-15 2004-11-23 Allergan, Inc. Clostridial toxin therapy for Hashimoto's thyroiditis
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US20050214327A1 (en) * 2000-06-02 2005-09-29 Allergan, Inc. Neurotoxin-containing suppositories and related methods
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
US6306403B1 (en) * 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
US7691983B2 (en) * 2000-07-21 2010-04-06 Allergan, Inc. Chimera botulinum toxin type E
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US7491799B2 (en) * 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US20040219619A1 (en) * 2000-07-21 2004-11-04 Ester Fernandez-Salas Methods of identifying compounds that alter toxin persistence and/or protease activity
GB0029125D0 (en) * 2000-11-29 2001-01-10 Specialistkliniken I Varberg H Novel treatment
JP4707254B2 (ja) * 2001-04-24 2011-06-22 クミアイ化学工業株式会社 粒状組成物及びその製造方法
BR0210873A (pt) * 2001-07-10 2004-06-22 Yamanouchi Pharma Co Ltd Composição farmacêutica para terapia de cistite intersticial
US6984375B2 (en) * 2001-08-03 2006-01-10 Allergan, Inc. Nuclei density and nuclei area methods for determining effects of a botulinum toxin on muscles
US8110217B2 (en) * 2001-08-13 2012-02-07 University Of Pittsburgh Sphingomyelin liposomes for the treatment of hyperactive bladder disorders
US20100104631A1 (en) * 2001-08-13 2010-04-29 Lipella Pharmaceuticals Inc. Method of treatment for bladder dysfunction
AU2002323151A1 (en) * 2001-08-13 2003-03-03 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
US7255866B2 (en) 2001-09-17 2007-08-14 Allergan, Inc. Botulinum toxin therapy for fibromyalgia
US6623742B2 (en) 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
KR20100135884A (ko) * 2001-11-15 2010-12-27 마이크로 알제 코포레이션 3, 4-프로피온퍼하이드로퓨린을 포함하는 약학 조성물 및 상기 조성물을 이용한 신경 전달의 블로킹 방법
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US7140371B2 (en) 2002-03-14 2006-11-28 Allergan, Inc. Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
US6688311B2 (en) 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US6776991B2 (en) * 2002-06-26 2004-08-17 Allergan, Inc. Methods for treating priapism
WO2004010934A2 (en) * 2002-07-29 2004-02-05 Rajiv Doshi Methods for the use of neurotoxin in the treatment of urologic disorders
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
US7238357B2 (en) * 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
GB2398636A (en) * 2003-02-21 2004-08-25 Ipsen Ltd Method for determining the quantity of pre-synaptic neuromuscular blocking substance contained in a sample
US8071550B2 (en) * 2003-03-03 2011-12-06 Allergan, Inc. Methods for treating uterine disorders
JP2007528352A (ja) * 2003-03-06 2007-10-11 ボツリヌム・トクシン・リサーチ・アソシエイツ・インコーポレイテッド 洞炎に関連する慢性の顔面痛および頭痛のボツリヌス毒素での治療
MXPA05009424A (es) * 2003-03-06 2006-02-10 Botulinum Toxin Res Ass Inc Tratamiento de chalazion cronico y hordeolum con la toxina botulinica.
US7396535B2 (en) * 2003-04-25 2008-07-08 Ackerman Alan H Therapy for obsessive compulsive head banging
US7393537B2 (en) * 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
US7422753B2 (en) * 2003-04-25 2008-09-09 Allergan, Inc. Methods for treating trichotillomania
US7390496B2 (en) * 2003-04-25 2008-06-24 Allergan, Inc. Therapeutic treatments for repetitive hand washing
US7393538B2 (en) * 2003-04-25 2008-07-01 Ackerman Alan H Clostridial toxin treatment for dermatillomania
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
US20050013850A1 (en) * 2003-07-15 2005-01-20 Caers Jan K. Device to assist hyperhydrosis therapy
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8609112B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8609113B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8617572B2 (en) 2003-10-29 2013-12-31 Allergan, Inc. Botulinum toxin treatments of depression
US20050096550A1 (en) * 2003-10-31 2005-05-05 Medtronic, Inc. Techniques for transrectal delivery of a denervating agent to the prostate gland
US7437194B2 (en) * 2003-10-31 2008-10-14 Medtronic, Inc. Stimulating the prostate gland
US20050096629A1 (en) * 2003-10-31 2005-05-05 Medtronic, Inc. Techniques for transurethral delivery of a denervating agent to the prostate gland
US20050096549A1 (en) * 2003-10-31 2005-05-05 Medtronic, Inc. Techniques for transperineal delivery of a denervating agent to the prostate gland
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
GB0328060D0 (en) 2003-12-04 2004-01-07 Sod Conseils Rech Applic Botulinum toxin treatment
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
US20050148935A1 (en) * 2003-12-29 2005-07-07 Rozalina Dimitrova Botulinum toxin injection guide
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US20080021051A1 (en) * 2004-05-07 2008-01-24 Phytotox Limited Phycotoxins and Uses Thereof
WO2005110418A2 (en) * 2004-05-07 2005-11-24 Phytotox Limited Transdermal administration of phycotoxins
US8173797B2 (en) * 2004-07-21 2012-05-08 Cornell Research Foundation, Inc. Therapeutic compounds derived from spider venom and their method of use
US20060024794A1 (en) * 2004-07-30 2006-02-02 Shengwen Li Novel methods for production of di-chain botulinum toxin
PL1776137T3 (pl) * 2004-08-04 2015-03-31 Ipsen Biopharm Ltd Kompozycja farmaceutyczna zawierająca neurotoksynę botulinową
WO2006013370A1 (en) 2004-08-04 2006-02-09 Ipsen Limited Pharmaceutical composition containing botulinum neurotoxin a2
US7179474B2 (en) * 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
US7429386B2 (en) 2004-09-03 2008-09-30 Allergan, Inc. Stretch mark treatment
US7727537B2 (en) 2005-02-14 2010-06-01 Dpm Therapeutics Corp. Stabilized compositions for topical administration and methods of making same
CN1930186A (zh) 2005-03-03 2007-03-14 阿勒根公司 为获得梭菌毒素的梭菌细菌培养基及方法
US7419675B2 (en) * 2005-05-26 2008-09-02 Allergan, Inc. Method for treating peritoneal adhesions
EP1896112A4 (en) * 2005-06-07 2011-04-27 A M S Res Corp INJECTION GUIDANCE SYSTEM AND METHOD
US20070038089A1 (en) * 2005-06-29 2007-02-15 Olympus Medical Systems Corp. Transurethral diagnostic method and treatment method using ultrasonic endoscope
JP5368793B2 (ja) 2005-07-18 2013-12-18 ユニバーシティ オブ マサチューセッツ ロウエル ナノエマルジョンを製造および使用するための組成物および方法
US7910116B2 (en) * 2005-08-24 2011-03-22 Allergan, Inc. Use of a botulinum toxin to improve gastric emptying and/or to treat GERD
EP1933813A4 (en) * 2005-10-11 2013-02-27 Univ Pittsburgh SPHINGOMYELIN LIPOSOME FOR THE TREATMENT OF HYPERACTIVE BLADDER DISORDER
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
CN101374498A (zh) 2005-12-01 2009-02-25 麻萨诸塞州洛厄尔大学 肉毒杆菌纳米乳液
US20090312696A1 (en) * 2005-12-28 2009-12-17 Copa Vincent G Devices, Systems, and Related Methods for Delivery of Fluid to Tissue
WO2007106874A2 (en) * 2006-03-14 2007-09-20 Autocraft Industries, Inc. Improved wheelchair
US7794386B2 (en) 2006-03-15 2010-09-14 Allergan, Inc. Methods for facilitating weight loss
US7811586B2 (en) * 2006-05-02 2010-10-12 Allergan, Inc. Methods for alleviating testicular pain
US20090304747A1 (en) * 2006-05-16 2009-12-10 Mayo Foundation For Medical Education And Research Use of dmso and botulinum toxin therapy for urinary incontinence and related disorders
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US20080092910A1 (en) * 2006-10-18 2008-04-24 Allergan, Inc. Apparatus and method for treating obesity using neurotoxins in conjunction with bariatric procedures
US20080113051A1 (en) * 2006-11-13 2008-05-15 Allergan, Inc. Methods for alleviating tattoo pain
WO2008070538A2 (en) * 2006-12-01 2008-06-12 Anterios, Inc. Micellar nanoparticles comprising botulinum toxin
CN107080703A (zh) 2006-12-01 2017-08-22 安特里奥公司 肽纳米粒子和其用途
CA2678038C (en) * 2007-02-15 2016-10-11 Allergan, Inc. Use of botulinum toxin and enzymes for treating bladder or prostate disorders, or hyperhydrosis
WO2008151022A2 (en) 2007-05-31 2008-12-11 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
RU2010120016A (ru) 2007-10-23 2011-11-27 Аллерган, Инк. (Us) Способы лечения хронического нейрогенного воспаления с применением модифицированных клостридиальных токсинов
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
CN102076333A (zh) * 2008-06-26 2011-05-25 安特里奥公司 真皮递送
CA2745657C (en) 2008-12-04 2022-06-21 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
CA2752506A1 (en) 2008-12-15 2010-06-24 Protox Therapeutics Inc. Method for treating prostatitis utilizing modified pore-forming protein proaerolysin
US20100166739A1 (en) * 2008-12-30 2010-07-01 Lipella Paharmaceuticals Inc. Methods and Compositions for Diagnosing Urological Disorders
US8133491B1 (en) 2009-01-30 2012-03-13 The University Of Toledo Compositions and methods for treatment of hyperplastic disorders
WO2010101968A1 (en) 2009-03-06 2010-09-10 Allergan, Inc. Clostridial toxin to improve ejaculate
US20100303794A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Glucagon Like Hormone Retargeted Endopepidases
US20100303791A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Glucagon Like Hormone Retargeted Endopepidases
US8198229B2 (en) * 2009-05-29 2012-06-12 Allergan, Inc. Methods of treating urogenital-neurological disorders using galanin retargeted endopepidases
US20100303783A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Tachykinin Retargeted Endopepidases
US20100303756A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Interleukin Retargeted Endopepidases
US20100303789A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Neurotrophin Retargeted Endopepidases
US20100303798A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Neurotrophin Retargeted Endopepidases
US20100303788A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Galanin Retargeted Endopepidases
US8147848B2 (en) 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
EP2482838A4 (en) 2009-09-30 2013-04-10 Toxcure Inc USE OF BOTULINUM NEUROTOXIN FOR THE TREATMENT OF SUBSTANCE DEPENDENCE
US9289607B2 (en) 2010-08-18 2016-03-22 Medtronic, Inc. Urgency therapy with neuromodulation and C-afferent nerve desensitization
WO2012109387A1 (en) 2011-02-08 2012-08-16 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
US20120207733A1 (en) * 2011-02-14 2012-08-16 Allergan, Inc. Treating a Disease of Hyperproliferation Using Retargeted Endopeptidases
US20140140983A1 (en) 2011-07-08 2014-05-22 Allergan, Inc. Method for treatment of autonomic nervous system disorders
US8992941B2 (en) 2011-07-08 2015-03-31 Allergan, Inc. Method for treatment of esophageal spasm
KR20140054055A (ko) 2011-07-14 2014-05-08 알러간, 인코포레이티드 성행위와 관련된 실금의 치료방법
BR112014001066A2 (pt) 2011-07-20 2017-02-21 Allergan Inc toxinas botulínicas para uso em um método para tratamento de depósitos adiposos
US20130171122A1 (en) * 2011-12-29 2013-07-04 Allergan, Inc. Endopeptidase and neurotoxin combination treatment of bladder disorders
EP2836200B1 (en) * 2012-04-08 2020-07-15 Urogen Pharma Ltd. Reverse thermal hydrogel preparations for use in the treatment of disorders of the urothelium
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11512372B2 (en) * 2015-02-03 2022-11-29 Höganäs Ab (Publ) Powder metal composition for easy machining
MA45492A (fr) 2016-06-23 2019-05-01 Hopitaux Paris Assist Publique Vecteurs viraux pour le traitement de l'hyperactivité vésicale neurogène
WO2018038301A1 (en) 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
KR20240023684A (ko) 2016-09-13 2024-02-22 알레간 인코포레이티드 안정화된 비단백질 클로스트리듐 독소 조성물
JP2019535829A (ja) 2016-11-21 2019-12-12 エイリオン セラピューティクス， インコーポレイテッド 大型薬剤の経皮送達
EP3470054B1 (en) 2017-10-11 2023-09-20 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US10525111B2 (en) 2017-10-12 2020-01-07 Hugel, Inc. Microstructure formulation techniques for botulinum toxin
US10792400B2 (en) 2017-10-12 2020-10-06 Hugel Inc. Microstructure formulation techniques for botulinum toxin
RU2687106C1 (ru) * 2017-12-19 2019-05-07 Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ФГБОУ ВО ВолгГМУ МЗ РФ Способ лечения синдрома гиперактивного мочевого пузыря
EP3825689A3 (en) 2018-11-29 2021-09-15 Hugel Inc. A cell-based method for determining an activity of botulinum toxin
CN110935009B (zh) * 2019-12-24 2023-07-11 云南南诏药业有限公司 科博肽制剂在制备治疗痔疮药物中的应用
RU2768606C1 (ru) * 2021-04-16 2022-03-24 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр колопроктологии имени А.Н. Рыжих" Министерства здравоохранения Российской Федерации Способ комбинированного хирургического лечения хронической анальной трещины со спазмом сфинктера методом иссечения трещины в сочетании с инъекцией ботулинического токсина типа А в дозировке 40 ЕД во внутренний анальный сфинктер под ультразвуковой навигацией

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4932936A (en) † 1988-01-29 1990-06-12 Regents Of The University Of Minnesota Method and device for pharmacological control of spasticity
JPH0642950Y2 (ja) * 1988-10-15 1994-11-09 株式会社マイコー ケース固定装置
US5919665A (en) * 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US5183462A (en) * 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5192751A (en) 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
ES2194025T3 (es) 1993-06-10 2003-11-16 Allergan Inc Toxinas botulinicas multiples para tratar trastornos y enfermedades neuromusculares.
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
DE69435302D1 (de) 1993-12-28 2010-08-26 Allergan Inc Neurotoxisches Komponent eines Botulinumtoxins zur Behandlung von Spätdyskinesie
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US5837265A (en) * 1996-03-08 1998-11-17 The Regents Of The University Of California Chemically-modified clostridiatoxin with improved properties
US5939070A (en) * 1996-10-28 1999-08-17 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
CN1480212B (zh) * 1997-07-15 2013-12-04 科罗拉多大学董事会 神经毒素疗法在泌尿系及相关疾病治疗中的应用
US7449192B2 (en) * 1997-07-15 2008-11-11 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction
US7470431B2 (en) * 1997-07-15 2008-12-30 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer
US7455845B2 (en) * 1997-07-15 2008-11-25 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure
US9066943B2 (en) 1997-07-15 2015-06-30 The Regents Of The University Of Colorado Use of botulinum toxin therapy for treatment of urological neurological conditions
JP3655061B2 (ja) * 1997-07-31 2005-06-02 株式会社ニデック 紫外線吸収性基材
JP2000214813A (ja) * 1999-01-22 2000-08-04 Mercury Enterprise:Kk 二輪及び三輪車輌・トラック・四輪車両へ搭載可能な可動式省エネ広告塔
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
JP2002132198A (ja) * 2000-10-25 2002-05-09 Sukenori Kiuchi 三輪自転車一体型移動式回転広告塔
JP2002306290A (ja) * 2001-04-19 2002-10-22 Takumi:Kk ターンテーブル
JP2007037725A (ja) * 2005-08-02 2007-02-15 Masahiro Matsubara 多機能立方体展示ユニット
JP3121792U (ja) * 2005-10-28 2006-06-01 株式会社イマジンクリエイション ラック付３ｄレンズ使用立体型看板

Also Published As

Publication number Publication date
EP1011695B2 (en) 2009-11-04
CN1803189B (zh) 2010-05-26
CN1651074A (zh) 2005-08-10
DE69835911T3 (de) 2011-01-13
AU2005234633B9 (en) 2009-09-03
JP3692033B2 (ja) 2005-09-07
ATE320815T1 (de) 2006-04-15
AU2005234633B2 (en) 2007-04-19
JP4672676B2 (ja) 2011-04-20
LU92250I2 (fr) 2013-09-10
EP1949909A1 (en) 2008-07-30
CN1480212A (zh) 2004-03-10
US6365164B1 (en) 2002-04-02
JP2005089478A (ja) 2005-04-07
PT1658858E (pt) 2010-02-26
ES2268567T3 (es) 2007-03-16
DK1502601T3 (da) 2007-01-15
JP3955061B2 (ja) 2007-08-08
EP1011695B1 (en) 2006-03-22
ES2268567T5 (es) 2010-11-02
JP5005753B2 (ja) 2012-08-22
CA2296720A1 (en) 1999-01-28
DK1475099T4 (da) 2014-05-19
JP2001510163A (ja) 2001-07-31
ES2385130T3 (es) 2012-07-18
DK1949909T3 (da) 2014-03-24
DE69833942D1 (de) 2006-05-11
EP2145629A3 (en) 2010-06-09
US20020025327A1 (en) 2002-02-28
ES2256945T5 (es) 2010-03-26
EP1011695A1 (en) 2000-06-28
EP1475099A1 (en) 2004-11-10
DE69833059T2 (de) 2006-08-03
US20040259788A1 (en) 2004-12-23
ES2450747T3 (es) 2014-03-25
KR100544060B1 (ko) 2006-01-23
CY1105816T1 (el) 2011-02-02
ES2336924T5 (es) 2014-04-30
EP1475099B2 (en) 2014-04-09
EP2246066A1 (en) 2010-11-03
PT1502601E (pt) 2006-12-29
JP2010043127A (ja) 2010-02-25
DK1011695T3 (da) 2006-05-01
JP2006063089A (ja) 2006-03-09
CN1939531A (zh) 2007-04-04
US7429387B2 (en) 2008-09-30
JP2008208136A (ja) 2008-09-11
LU92055I2 (fr) 2013-10-10
EP1658858B1 (en) 2009-11-18
US6667041B2 (en) 2003-12-23
EP2145629A2 (en) 2010-01-20
ES2336924T3 (es) 2010-04-19
JP4053559B2 (ja) 2008-02-27
JP4696082B2 (ja) 2011-06-08
DK1475099T3 (da) 2006-03-13
ES2255025T5 (es) 2014-06-16
ES2255025T3 (es) 2006-06-16
EP1502601A1 (en) 2005-02-02
DE69835911D1 (de) 2006-10-26
HK1091750A1 (en) 2007-01-26
PT1011695E (pt) 2006-07-31
EP2145629B1 (en) 2012-04-04
DE69833059T3 (de) 2014-12-18
CN1135988C (zh) 2004-01-28
EP1011695A4 (en) 2004-05-26
ES2256945T3 (es) 2006-07-16
EP1502601B2 (en) 2010-07-21
ATE552006T1 (de) 2012-04-15
PT2145629E (pt) 2012-04-16
DE69835911T2 (de) 2007-01-11
DK2145629T3 (da) 2012-05-29
ATE448792T1 (de) 2009-12-15
EP1475099B1 (en) 2005-12-28
EP1658858A3 (en) 2006-07-05
DK1658858T3 (da) 2010-04-06
JP2006104221A (ja) 2006-04-20
EP1658858A2 (en) 2006-05-24
WO1999003483A1 (en) 1999-01-28
AU8300798A (en) 1999-02-10
CN1803189A (zh) 2006-07-19
CN1480212B (zh) 2013-12-04
KR20010021941A (ko) 2001-03-15
JP2007091756A (ja) 2007-04-12
ATE339220T1 (de) 2006-10-15
HK1119396A1 (en) 2009-03-06
DE69841291D1 (de) 2009-12-31
DE69833059D1 (de) 2006-02-02
CN1321683C (zh) 2007-06-20
AU743085B2 (en) 2002-01-17
CA2296720C (en) 2008-01-29
CY1109827T1 (el) 2014-09-10
US7001602B2 (en) 2006-02-21
DE69833942T3 (de) 2010-06-10
HK1080377A1 (en) 2006-04-28
EP1658858B2 (en) 2014-03-26
EP1949909B1 (en) 2014-01-08
ATE314085T1 (de) 2006-01-15
AU2005234633C1 (en) 2011-02-10
JP2007126477A (ja) 2007-05-24
JP2005089479A (ja) 2005-04-07
DK1011695T4 (da) 2010-02-01
DK1502601T4 (da) 2010-11-08
CN1270527A (zh) 2000-10-18
EP1502601B1 (en) 2006-09-13
PT1949909E (pt) 2014-03-11
US20040126380A1 (en) 2004-07-01
CA2505930A1 (en) 1999-01-28
CA2570406C (en) 2012-02-14
CA2521392A1 (en) 1999-01-28
DE69833942T2 (de) 2006-09-07
CA2505930C (en) 2008-01-29
CA2570406A1 (en) 1999-01-28
CA2505933A1 (en) 1999-01-28
EP1637157A1 (en) 2006-03-22
CA2505933C (en) 2008-09-30
AU2005234633A1 (en) 2005-12-15
CN100518816C (zh) 2009-07-29
HK1064044A1 (en) 2005-01-21
JP4815468B2 (ja) 2011-11-16
CY1113355T1 (el) 2016-06-22
US7153514B2 (en) 2006-12-26
US20050159337A1 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
DK1658858T4 (da) Anvendelse af botulinumtoksin til behandling af rekalcitrant tømningsdysfunktion
MA25820A1 (fr) Combinaisons d'inhibiteurs de peptidase iv de dipeptidyle et d'autres agents antidiabetiques pour le traitement du mellitus de diabete.
DK0605501T5 (da) Anvendelse af præsynaptisk neurotoksin til behandling af cerebel parese
JP2005524663A5 (da)
DK1225881T3 (da) Anvendelsen af dapoxetin, en hurtigt-virkende selektiv serotonin genoptagelseshæmmer, til behandling af seksuel dysfunktion
SE9202208L (sv) Vävnadsförstärkning
DE69827392D1 (de) Protonenpumpenhemmer als kombinationstherapeutika mit antibakterielle wirkenden substanzen
SU1171035A1 (ru) Способ лечени сифилиса
RU96109846A (ru) Способ профилактики генерализации септической инфекции в раннем послеродовом периоде
ES2194860T3 (es) Composiciones que contienen timosina alfa 1 destinadas al tratamiento de pacientes que sufren una enfermedad hepatica descompensada.
ITGE930069A1 (it) Dispositivo ausiliario automatico per siringhe preriempite per facilitare l'introduzione dell'ago nel corpo del paziente.
RU99111088A (ru) Способ лечения инфекции streptococcus pneumoniae
GR3008320T3 (da)
FR2709963B1 (fr) Composition dermocosmétique, antifongique, notamment utile dans le traitement de dermites séborréhiques.
IT8602921A0 (it) Dell'iniezione direttamente alla valvolina speciale per ricircolo pompa. del gasolio di rifiuto
DE60121449D1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon
RU97102947A (ru) Способ лечения диффузного токсического зоба